JP2016500260A - 新規方法 - Google Patents

新規方法 Download PDF

Info

Publication number
JP2016500260A
JP2016500260A JP2015547149A JP2015547149A JP2016500260A JP 2016500260 A JP2016500260 A JP 2016500260A JP 2015547149 A JP2015547149 A JP 2015547149A JP 2015547149 A JP2015547149 A JP 2015547149A JP 2016500260 A JP2016500260 A JP 2016500260A
Authority
JP
Japan
Prior art keywords
cell
cells
gene
tet3
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015547149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016500260A5 (enExample
Inventor
レイク ウォルフ
レイク ウォルフ
ピート ジュリアン
ピート ジュリアン
ホレ ティモシィ
ホレ ティモシィ
クルエゲル クリステル
クルエゲル クリステル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Babraham Institute
Original Assignee
Babraham Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Institute filed Critical Babraham Institute
Publication of JP2016500260A publication Critical patent/JP2016500260A/ja
Publication of JP2016500260A5 publication Critical patent/JP2016500260A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
JP2015547149A 2012-12-17 2013-12-17 新規方法 Pending JP2016500260A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1222693.2A GB201222693D0 (en) 2012-12-17 2012-12-17 Novel method
GB1222693.2 2012-12-17
PCT/GB2013/053317 WO2014096800A1 (en) 2012-12-17 2013-12-17 Novel method

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018218938A Division JP2019058176A (ja) 2012-12-17 2018-11-22 新規方法

Publications (2)

Publication Number Publication Date
JP2016500260A true JP2016500260A (ja) 2016-01-12
JP2016500260A5 JP2016500260A5 (enExample) 2017-02-02

Family

ID=47630838

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015547149A Pending JP2016500260A (ja) 2012-12-17 2013-12-17 新規方法
JP2018218938A Pending JP2019058176A (ja) 2012-12-17 2018-11-22 新規方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018218938A Pending JP2019058176A (ja) 2012-12-17 2018-11-22 新規方法

Country Status (8)

Country Link
US (2) US20160186207A1 (enExample)
EP (1) EP2931881A1 (enExample)
JP (2) JP2016500260A (enExample)
CN (1) CN105051188A (enExample)
AU (1) AU2013366092A1 (enExample)
CA (1) CA2894822A1 (enExample)
GB (1) GB201222693D0 (enExample)
WO (1) WO2014096800A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037001A2 (en) 2008-09-26 2010-04-01 Immune Disease Institute, Inc. Selective oxidation of 5-methylcytosine by tet-family proteins
HK1198547A1 (en) 2011-07-29 2015-05-15 剑桥表现遗传学有限公司 Methods for detection of nucleotide modification
WO2014083118A1 (en) 2012-11-30 2014-06-05 Cambridge Epigenetix Limited Oxidising agent for modified nucleotides
GB201403216D0 (en) 2014-02-24 2014-04-09 Cambridge Epigenetix Ltd Nucleic acid sample preparation
CN104630272A (zh) * 2015-01-06 2015-05-20 西北农林科技大学 一种基于去甲基化促进生殖干细胞自我更新和增殖的载体及其应用
BR112018011089A2 (pt) 2015-12-04 2018-12-04 Intellia Therapeutics Inc composições e métodos para a imuno-oncologia
US20200087629A1 (en) * 2016-10-19 2020-03-19 Fred Hutchinson Cancer Research Center Compositions and methods for reprogramming cells and for somatic cell nuclear transfer using duxc expression
JP2020513832A (ja) 2017-03-22 2020-05-21 ノバルティス アーゲー 免疫腫瘍学のための組成物および方法
SG11201909866VA (en) * 2017-05-29 2019-11-28 Agency Science Tech & Res Markers of totipotency and methods of use
WO2019164876A1 (en) * 2018-02-20 2019-08-29 The Regents Of The University Of California Therapeutics that invoke epigenetic changes for use in treating neurological conditions such as cognitive impairment
WO2020028617A1 (en) * 2018-08-01 2020-02-06 University Of Georgia Research Foundation, Inc. Compositions and methods for improving embryo development

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069666A1 (ja) * 2005-12-13 2007-06-21 Kyoto University 核初期化因子
WO2010037001A2 (en) * 2008-09-26 2010-04-01 Immune Disease Institute, Inc. Selective oxidation of 5-methylcytosine by tet-family proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CELL, DEC-07-2012, VOL.151, P.1200-1213, JPN6017036972, ISSN: 0003648364 *
MUS MUSCULUS TET3 ISOFORM 1 MRNA, COMPLETE CDS, ALTERNATIVELY SPLICED, DATABASE GENBANK [ONLINE], AC, JPN6017036973, ISSN: 0003648365 *
NATURE, 2011, VOL.477, P.606-610, JPN6017036974, ISSN: 0003648366 *
日経バイオテク／日経バイオビジネス編, 日経バイオ最新用語辞典 第５版, 日経ＢＰ社, ４８０ページ, JPN6017036975, ISSN: 0003648367 *

Also Published As

Publication number Publication date
CA2894822A1 (en) 2014-06-26
US20190264223A1 (en) 2019-08-29
CN105051188A (zh) 2015-11-11
AU2013366092A1 (en) 2015-07-02
WO2014096800A1 (en) 2014-06-26
US20160186207A1 (en) 2016-06-30
EP2931881A1 (en) 2015-10-21
JP2019058176A (ja) 2019-04-18
GB201222693D0 (en) 2013-01-30

Similar Documents

Publication Publication Date Title
US20190264223A1 (en) Novel method
EP2989199B1 (en) Isolated naive pluripotent stem cells and methods of generating same
JP4901471B2 (ja) 体細胞核初期化物質のスクリーニング方法
JP6231253B2 (ja) 体細胞を再プログラムするためのｒｎａの使用
JP2022031941A (ja) 体細胞の再プログラミング
AU2019305586A1 (en) Chimeric antigen receptor T cells derived from immunoengineered pluripotent stem cells
US20190376045A1 (en) Immunoengineered pluripotent cells
AU2020274027A1 (en) Modified pluripotent cells
JP2017517256A (ja) 遺伝子配列を編集する方法
US20240091274A1 (en) TRANSPLANTED CELL PROTECTION VIA Fc SEQUESTRATION
CN104024404A (zh) 单倍体细胞
JP2021520215A (ja) リプログラミングベクター
WO2022086956A1 (en) Methods for generating formative pluripotent stem cells competent for direct primordial germ cell induction
Rodriguez-Polo et al. A piggyBac-based platform for genome editing and clonal rhesus macaque iPSC line derivation
CN104884612A (zh) Mait样细胞及其制作方法
KR20230118595A (ko) 털 매머드 대립 유전자를 이용한 유전자 편집을 위한조성물 및 방법
WO2013181641A1 (en) Totipotent stem cells
WO2006041910A2 (en) Stem cells derived from uniparental embryos and methods of use thereof
WO2012165740A1 (en) Composition for improving dedifferentiation of cells and method for producing inducted pluripotent stem cells using the same
Sato et al. The generation of viable, structurally integrated human-mouse chimaeras through enhanced hPSCs proliferation
WO2024182558A1 (en) Fluorescent cone reporter ips cells, retinal organoids and uses thereof
Li Von Hippel‐Lindau disease: An iPSC based model to identify mechanisms in hereditary cancer
CA2598022A1 (en) Method for removing desired chromosome and tailor-made medical treatment utilizing the same
Rodríguez Polo Non-human primate iPS cells for cell replacement therapies and human cardiovascular disease modeling
Ajduk Session 5. Stem Cells and Regenerative Medicine

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180724